Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

Corcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in ...

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the ...

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

The latest results, which J&J shared at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this ...